1
|
Hsieh CY, Lin CC, Chang WC. Taxanes in the Treatment of Head and Neck Squamous Cell Carcinoma. Biomedicines 2023; 11:2887. [PMID: 38001888 PMCID: PMC10669519 DOI: 10.3390/biomedicines11112887] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2023] [Revised: 10/22/2023] [Accepted: 10/24/2023] [Indexed: 11/26/2023] Open
Abstract
Taxanes, particularly docetaxel (DTX), has been widely used for combination therapy of head and neck squamous cell carcinoma (HNSCC). For locally advanced unresectable HNSCC, DTX combined with cisplatin and 5-fluorouracil as a revolutionary treatment revealed an advantage in the improvement of patient outcome. In addition, DTX plus immune check inhibitors (ICIs) showed low toxicity and an increased response of patients with recurrent or metastatic HNSCC (R/M HNSCC). Accumulated data indicate that taxanes not only function as antimitotics but also impair diverse oncogenic signalings, including angiogenesis, inflammatory response, ROS production, and apoptosis induction. However, despite an initial response, the development of resistance remains a major obstacle to treatment response. Taxane resistance could result from intrinsic mechanisms, such as enhanced DNA/RNA damage repair, increased drug efflux, and apoptosis inhibition, and extrinsic effects, such as angiogenesis and interactions between tumor cells and immune cells. This review provides an overview of taxanes therapy applied in different stages of HNSCC and describe the mechanisms of taxane resistance in HNSCC. Through a detailed understanding, the mechanisms of resistance may help in developing the potential therapeutic methods and the effective combination strategies to overcome drug resistance.
Collapse
Affiliation(s)
- Ching-Yun Hsieh
- Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan;
| | - Ching-Chan Lin
- Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan;
| | - Wei-Chao Chang
- Center for Molecular Medicine, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan
| |
Collapse
|
2
|
Laccourreye O, Marret G, Rubin F, Fabre E, Badoual C, Oudard S, Bonfils P, Lisan Q. Ten‐year outcome of curative “exclusive” chemotherapy in N0M0 squamous cell carcinoma of the larynx and pharynx with complete clinical response. Head Neck 2019; 41:2190-2196. [DOI: 10.1002/hed.25674] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2018] [Revised: 01/08/2019] [Accepted: 01/10/2019] [Indexed: 11/08/2022] Open
Affiliation(s)
- Ollivier Laccourreye
- Department of Otorhinolaryngology ‐ Head and Neck SurgeryUniversité Paris Descartes Sorbonne Paris Cité, Hôpital Européen Georges Pompidou Paris France
| | - Grégoire Marret
- Department of Medical OncologyUniversité Paris Descartes Sorbonne Paris Cité, Hôpital Européen Georges Pompidou Paris France
| | | | - Elizabeth Fabre
- Department of Medical OncologyUniversité Paris Descartes Sorbonne Paris Cité, Hôpital Européen Georges Pompidou Paris France
| | - Cécile Badoual
- Department of PathologyUniversité Paris Descartes Sorbonne Paris Cité, Hôpital Européen Georges Pompidou Paris France
| | - Stéphane Oudard
- Department of Medical OncologyUniversité Paris Descartes Sorbonne Paris Cité, Hôpital Européen Georges Pompidou Paris France
| | - Pierre Bonfils
- Department of Otorhinolaryngology ‐ Head and Neck SurgeryUniversité Paris Descartes Sorbonne Paris Cité, Hôpital Européen Georges Pompidou Paris France
| | - Quentin Lisan
- Department of Otorhinolaryngology ‐ Head and Neck SurgeryUniversité Paris Descartes Sorbonne Paris Cité, Hôpital Européen Georges Pompidou Paris France
| |
Collapse
|
3
|
Shi J, Gao P, Song Y, Chen X, Li Y, Zhang C, Wang H, Wang Z. Efficacy and safety of taxane-based systemic chemotherapy of advanced gastric cancer: A systematic review and meta-analysis. Sci Rep 2017; 7:5319. [PMID: 28706257 PMCID: PMC5509659 DOI: 10.1038/s41598-017-05464-0] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2016] [Accepted: 05/31/2017] [Indexed: 02/07/2023] Open
Abstract
Taxanes are chemotherapeutic agents commonly used to treat several cancers. However, the effects of taxanes on advanced gastric cancer (AGC) are still not clear, especially when used as a first-line treatment. This systematic review and meta-analysis aims to investigate the efficacy and safety of taxanes as a first-line treatment of AGC. The quality of our included studies was assessed using the Cochrane risk of bias tool for RCTs and NOS scale for nRCTs, and the data of the included studies was of satisfactory quality to analyze. The outcomes included overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and toxicity. Taxanes significantly improved OS (HR = 0.84, 95% CI 0.76-0.92, P = 0.0004) and had a slight effect on ORR (RR = 1.23, 95% CI 1.00-1.51, P = 0.05). However, taxanes may also increase the risks of neutropenia and leucopenia, similar to effects observed in other conventional chemotherapeutic treatments such as oxaliplatin and epirubicin. Therefore, patient characteristics including concomitant diseases, physical condition, and prior therapies should be considered before selecting taxane-based treatments for AGC.
Collapse
Affiliation(s)
- Jinxin Shi
- Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, 155 North Nanjing Street, Heping District, Shenyang, 110001, China
| | - Peng Gao
- Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, 155 North Nanjing Street, Heping District, Shenyang, 110001, China
| | - Yongxi Song
- Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, 155 North Nanjing Street, Heping District, Shenyang, 110001, China
| | - Xiaowan Chen
- Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, 155 North Nanjing Street, Heping District, Shenyang, 110001, China
| | - Yuan Li
- Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, 155 North Nanjing Street, Heping District, Shenyang, 110001, China
| | - Changwang Zhang
- Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, 155 North Nanjing Street, Heping District, Shenyang, 110001, China
| | - Hongchi Wang
- Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, 155 North Nanjing Street, Heping District, Shenyang, 110001, China
| | - Zhenning Wang
- Department of Surgical Oncology and General Surgery, First Hospital of China Medical University, 155 North Nanjing Street, Heping District, Shenyang, 110001, China.
| |
Collapse
|
4
|
Vidal L, Ben Aharon I, Limon D, Cohen E, Popovtzer A. Role of Induction Chemotherapy Prior to Chemoradiation in Head and Neck Squamous Cell Cancer-Systematic Review and Meta-analysis. Cancer J 2017; 23:79-83. [PMID: 28410291 DOI: 10.1097/ppo.0000000000000253] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The objective of this study was to review and assess the impact of additional induction chemotherapy to concomitant chemoradiation in head and neck squamous cell cancer. We performed a comparative systematic review and meta-analysis of clinical trials of induction chemotherapy + chemoradiation and chemoradiation alone in this setting. We identified trials randomizing 1314 patients (published 2004-2015). A non-statistically significant trend was observed in favor of induction chemotherapy + chemoradiation on overall survival (hazard ratio, 0.88; 95% confidence interval, 0.75-1.04). Disease control was superior in the induction chemotherapy + chemoradiation group (hazard ratio, 0.69; 95% confidence interval, 0.57-0.83). The rate of complete response improved with induction chemotherapy compared with concomitant chemoradiation (relative risk, 1.52; 95% confidence interval, 1.20-1.92). This study showed no benefit of induction chemotherapy + chemoradiation on overall survival. However, improved complete response rate and death certificate-only registrations may imply that selected patients may benefit from induction chemotherapy.
Collapse
Affiliation(s)
- Liat Vidal
- From the *Davidoff Cancer Center, Rabin Medical Center-Beilinson Hospital, Petah Tikva; †Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; and ‡Division of Hematology/Oncology, Department of Medicine, and Translational Science, UC San Diego Moores Cancer Center, La Jolla, CA
| | | | | | | | | |
Collapse
|
5
|
Wei FQ, Sun W, Wong TS, Gao W, Wen YH, Wei JW, Wei Y, Wen WP. Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH : CR 2016; 35:18. [PMID: 26795730 PMCID: PMC4722756 DOI: 10.1186/s13046-016-0295-1] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/11/2015] [Accepted: 01/17/2016] [Indexed: 11/10/2022]
Abstract
BACKGROUND Dendritic cells (DCs) have been used successfully in clinical pilot studies. However, tumor-specific immunity and clinical responses were only induced in certain cancer patients. It has been well documented that immunotherapy efficacy can be optimized for responses using antigen pulsing. METHODS The human laryngeal squamous cell cancer (LSCC) cell line SNU899 was used to evaluate the in vitro anti-tumor efficacy of three different preparations of dendritic cell (DC) vaccines consisting of either whole tumor cells or their derivatives including: i) DCs pulsed with a tumor cell supernatant (DC-TCS), ii) DCs pulsed with whole-cell tumor stressed lysate (DC-TSL), and iii) DCs pulsed with irradiated tumor cells (DC-ITC). RESULTS Our results showed that DC-TSL is an effective source of tumor-associated antigens (TAAs) for pulsing DCs. DC-TSL induced the highest expansion of TAA-specific T cells, the strongest Th1 cytokine response, and the most potent cytotoxic T lymphocyte (CTL) activity. DC-TCS and DC-ITC inhibited T cell activation but induced a certain extent of CTL activity. CONCLUSIONS These data suggest that DC-TSL is a more potent inducer of antitumor immunity against laryngeal cancer than other antigen-loading strategies using whole tumor cell materials. This strategy provides an alternative approach for DC-based immunotherapy for laryngeal cancer.
Collapse
Affiliation(s)
- Fan-Qin Wei
- Department of Otorhinolaryngology Head and Neck Surgery, the First Affiliated Hospital of Sun Yat-sen University, 2nd Zhongshan Road 58#, Guangzhou, 510080, Guangdong, P.R. China. .,Institute of Otorhinolaryngology Head and Neck Surgery, Sun Yat-sen University, 2nd Zhongshan Road 58#, Guangzhou, 510080, Guangdong, P.R. China. .,Department of Otorhinolaryngology Head and Neck Surgery, the Sixth Affiliated Hospital of Sun Yat-Sen University, Yuancun Second Cross Road 26#, Guangzhou, 510655, Guangdong, P.R. China.
| | - Wei Sun
- Department of Otorhinolaryngology Head and Neck Surgery, the First Affiliated Hospital of Sun Yat-sen University, 2nd Zhongshan Road 58#, Guangzhou, 510080, Guangdong, P.R. China.
| | - Thian-Sze Wong
- Department of Surgery, The University of Hong Kong, Pokfulam Road 102#, Hong Kong, P.R. China.
| | - Wei Gao
- Department of Surgery, The University of Hong Kong, Pokfulam Road 102#, Hong Kong, P.R. China.
| | - Yi-Hui Wen
- Department of Otorhinolaryngology Head and Neck Surgery, the First Affiliated Hospital of Sun Yat-sen University, 2nd Zhongshan Road 58#, Guangzhou, 510080, Guangdong, P.R. China. .,Institute of Otorhinolaryngology Head and Neck Surgery, Sun Yat-sen University, 2nd Zhongshan Road 58#, Guangzhou, 510080, Guangdong, P.R. China.
| | - Jia-Wei Wei
- Department of Otorhinolaryngology Head and Neck Surgery, the First Affiliated Hospital of Sun Yat-sen University, 2nd Zhongshan Road 58#, Guangzhou, 510080, Guangdong, P.R. China. .,Institute of Otorhinolaryngology Head and Neck Surgery, Sun Yat-sen University, 2nd Zhongshan Road 58#, Guangzhou, 510080, Guangdong, P.R. China.
| | - Yi Wei
- Department of Otorhinolaryngology Head and Neck Surgery, the First Affiliated Hospital of Sun Yat-sen University, 2nd Zhongshan Road 58#, Guangzhou, 510080, Guangdong, P.R. China. .,Institute of Otorhinolaryngology Head and Neck Surgery, Sun Yat-sen University, 2nd Zhongshan Road 58#, Guangzhou, 510080, Guangdong, P.R. China.
| | - Wei-Ping Wen
- Department of Otorhinolaryngology Head and Neck Surgery, the First Affiliated Hospital of Sun Yat-sen University, 2nd Zhongshan Road 58#, Guangzhou, 510080, Guangdong, P.R. China. .,Institute of Otorhinolaryngology Head and Neck Surgery, Sun Yat-sen University, 2nd Zhongshan Road 58#, Guangzhou, 510080, Guangdong, P.R. China.
| |
Collapse
|
6
|
Asakage T, Ando M, Yoshida M, Saito Y, Omura G, Yamasoba T. [Retrospective Study of Laryngeal Preservation Treatment for Hypopharyngeal Carcinoma with Transoral Resection or Induction Chemotherapy]. NIHON JIBIINKOKA GAKKAI KAIHO 2015; 118:1118-23. [PMID: 26615662 DOI: 10.3950/jibiinkoka.118.1118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
We have performed transoral surgical resection for patients with T1/T2 hypopharyngeal cancer and induction chemotherapy with docetaxel for patients with T2/T3 disease. The patients were analyzed in order to determine the current situation of larynx preservation in patients with hypopharyngeal cancer. The data of a total of 83 patients with hypopharyngeal cancer were analyzed retrospectively. The primary subsites were : pyriform sinus (PS) in 61 patients, posterior wall (PW) in 13 patients, and postcricoid (PC) in 9 patients. The number of patients classified as having T1, T2, T3 and T4 disease were 14, 29, 23 and 17, respectively. The main therapies employed in the patients were as follows: transoral surgical resection plus radiation therapy for T1 disease, radiation therapy, induction chemotherapy, and partial resection for T2 disease, induction chemotherapy, radiation therapy, and pharyngo-laryngoesophagectomy for T3 disease, and pharyngo-laryngoesophagectomy plus induction chemotherapy for T4 disease. The 5-year larynx preservation rates in the patients with T1, T2, T3 and T4 disease were 100%, 73%, 39% and 35%, respectively. Our method was able to improve the larynx preservation rate without having any adverse effect on the survival rate. However, the strength of treatment for T 3 disease needs to be improved, because a large number of recurrences and deaths due to the primary disease were encountered in this patient group.
Collapse
|
7
|
Lin C, Wang Z, Li L, He Y, Fan J, Liu Z, Zhao S, Ju D. The role of autophagy in the cytotoxicity induced by recombinant human arginase in laryngeal squamous cell carcinoma. Appl Microbiol Biotechnol 2015; 99:8487-94. [DOI: 10.1007/s00253-015-6565-6] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2015] [Revised: 03/20/2015] [Accepted: 03/20/2015] [Indexed: 10/23/2022]
|